2. Search Result
Search Result
Results for "

coagulation factors

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

3

Fluorescent Dye

3

Biochemical Assay Reagents

4

Peptides

4

Inhibitory Antibodies

1

Natural
Products

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1560
    Bismuth subgallate
    1 Publications Verification

    		 Factor Xa Others
    Bismuth subgallate, a hemostatic agent, acts on coagulation factor XII (Hageman factor), leading to the activation of the coagulation cascade and improving early formation of a fibrin clot .
    Bismuth subgallate
  • HY-P4245
    D-Pro-Phe-Arg-Chloromethylketone

    		Factor Xa Kallikrein Cardiovascular Disease Neurological Disease
    D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation .
    D-Pro-Phe-Arg-Chloromethylketone
  • HY-114128
    Turoctocog alfa

    		Factor VIII Others
    Turoctocog alfa is a recombinant coagulation factor VIII (FVIII) from chinese hamster ovary (CHO) cells. Turoctocog alfa can be used for researching haemophilia A .
    Turoctocog alfa
  • HY-P990060
    Denecimig

    Mim8

    		 Factor Xa Cardiovascular Disease
    Denecimig (Mim8) is a novel activated coagulation factor VIII-mimetic human bispecific antibody with anti-FIXa and anti-FX arms that potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo .
    Denecimig
  • HY-D2466
    Dextran-CY3

    		Fluorescent Dye Infection Cardiovascular Disease Cancer
    Dextran-CY3 is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander .
    Dextran-CY3
  • HY-D2421
    DEAE-dex-Cy5

    		Fluorescent Dye Cardiovascular Disease Cancer
    DEAE-dex-Cy5 is a fluorescent labeling reagent that combines Cy5 (HY-D0821) fluorescent dye, Dextran (dex) and Diethylaminoethyl (DEAE). Cy5 is a Cyanine dye (with a long wavelength about 662nm) that can be used for molecular labeling and microscopy imaging. Dex has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander .
    DEAE-dex-Cy5
  • HY-D2460
    Dextran-CY5.5

    		Fluorescent Dye Bacterial Cardiovascular Disease Cancer
    Dextran-CY5.5 is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673nm and the emission wavelength is 707nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander .
    Dextran-CY5.5
  • HY-E70393C
    Human Factor XIa

    		Others Others
    Human Factor XIa is a blood coagulation protease. Human Factor XIa activates the Factor IX and Factor V, resulting in the generation of thrombin and fibrin .
    Human Factor XIa
  • HY-E70393B
    Human Factor Xa

    		Others Others
    Human Factor Xa is a blood coagulation protease. Human Factor Xa is used in research of novel anticoagulant development .
    Human Factor Xa
  • HY-E70393E
    Human Factor XIIa Beta

    		Angiotensin Receptor Others
    Human Factor XIIa Beta is the active fragment of coagulation factor XII, that participates in the intrinsic pathway of coagulation, and leads to the formation of blood clots. Human Factor XIIa Beta also participates in the kinin-generating pathway, which leads to the release of bradykinin (vasodilator). Human Factor XIIa Beta stimulates the release of catecholamines, and mediates its cardiovascular effects through a noncholinergic angiotensin-converting enzyme (ACE)-regulated mechanism .
    Human Factor XIIa Beta
  • HY-112624
    Dextran

    Dextran 40

    		 Bacterial Cardiovascular Disease Cancer
    Dextran (Dextran 40) has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander.
    Dextran
  • HY-P99769
    Omfiloctocog alfa

    SCT-800

    		 Factor VIII Metabolic Disease
    Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A .
    Omfiloctocog alfa
  • HY-112998
    Efmoroctocog alfa

    		Factor VIII Others
    Efmoroctocog alfa is a recombinant human coagulation factor VIII-Fc fusion protein (rFVIIIFc) that can be used for the research of haemophilia A .
    Efmoroctocog alfa
  • HY-B2172
    Vitamin K

    		Endogenous Metabolite Cardiovascular Disease Cancer
    Vitamin K, the blood-clotting vitamin, is important for the function of numerous proteins within the body, such as the coagulation factors, osteocalcin and matrix-Gla protein.
    Vitamin K
  • HY-B0385
    Gabexate mesylate
    4 Publications Verification

    FOY

    		 Proteasome Factor Xa Inflammation/Immunology
    Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with Kis of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with Kis of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .
    Gabexate mesylate
  • HY-E70393D
    Human Factor Alpha XIIa

    		Others Others
    Human Factor Alpha XIIa is a blood coagulation protease, which increases the clotting potential. Human Factor Alpha XIIa exhibits a fibrinolysis protein homologous heavy chain, indicating its function in fibrinolysis .
    Human Factor Alpha XIIa
  • HY-E70393
    Human Factor VIIa

    		Factor VIIa Others
    Human Factor VIIa is a vitamin K-dependent serine protease that is involved in the blood coagulation process. Human Factor VIIa activates Factor X, which causes the conversion of prothrombin to thrombin and the conversion of fibrinogen to fibrin, leading to the formation of blood clots. Human Factor VIIa exhibits the potential to ameliorate Hemophilia .
    Human Factor VIIa
  • HY-17567A
    Heparin sodium salt
    Maximum Cited Publications
    40 Publications Verification

    Sodium heparin; Sodium heparinate

    		 Thrombin Factor Xa Autophagy Cardiovascular Disease Cancer
    Heparin sodium salt (Sodium heparin) is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa. Heparin sodium salt significantly inhibits exosome-cell interactions.
    Heparin sodium salt
  • HY-E70393I
    Bovine Factor IXa Beta

    		Others Others
    Bovine Factor IXa Beta is an inactive and highly specific enzyme, with a minimal extended substrate recognition site and a preference for particular amino acid residues at specific subsites. Bovine Factor IXa Beta plays a role in the blood coagulation cascade .
    Bovine Factor IXa Beta
  • HY-P4576
    Methoxycarbonyl-D-Nle-Gly-Arg-pNA

    		Factor Xa Others
    Methoxycarbonyl-D-Nle-Gly-Arg-pNA is a synthetic trypsin that can serve as a substrate for coagulation factors IXa (FIXa) and Xa (FXa) .
    Methoxycarbonyl-D-Nle-Gly-Arg-pNA
  • HY-10777
    EMD 495235

    		Factor Xa Cardiovascular Disease
    EMD 495235 is a potent and orally active coagulation factor Xa inhibitor with an IC50 of 5.5 nM and a Ki of 6.8 nM. EMD 495235 shows anticoagulant activities .
    EMD 495235
  • HY-B0385R
    Gabexate mesylate (Standard)

    		Proteasome Factor Xa Inflammation/Immunology
    Gabexate (mesylate) (Standard) is the analytical standard of Gabexate (mesylate). This product is intended for research and analytical applications. Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with Kis of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with Kis of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .
    Gabexate mesylate (Standard)
  • HY-156613
    Frunexian

    EP-7041

    		 Factor Xa Cardiovascular Disease
    Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, targeting to factor XIa. Frunexian exhibits antithrombotic activity, with no bleeding liability in rat mesenteric arterial puncture model. Frunexian can be used in extracorporeal membrane oxygenation (ECMO) research .
    Frunexian
  • HY-E70393J
    Bovine Factor XIa

    		Others Others
    Bovine Factor XIa is an enzyme, which is involved in the intrinsic pathway of blood coagulation. Bovine Factor XIa is highly selective and exhibits a minimal extended substrate recognition site of at least five residues long. Bovine Factor XIa is reactive as Bovine Factor IXa (HY-E70393I) does, that it cleaves all the peptides bearing factor IX activation site sequences .
    Bovine Factor XIa
  • HY-118803
    AS1468240

    		Factor Xa Others
    AS1468240 is an orally active inhibitor for anticoagulant factor Xa (fXa), that inhibits human fXa with IC50 of 8.7 nM. AS1468240 prolongs the coagulation time in mice .
    AS1468240
  • HY-NP018
    Bovine fibrinogen (from plasma)

    FGA; FGA protein

    		 NF-κB Inflammation/Immunology
    Bovine fibrinogen (from fibrinogen) is a native fibrinogen from bovine plasma. Bovine fibrinogen (from fibrinogen) can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 .
    Bovine fibrinogen (from plasma)
  • HY-113958
    Difethialone

    LM-2219

    		 VD/VDR Others
    Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
    Difethialone
  • HY-17567C
    Heparin sodium salt (MW 15kDa)
    1 Publications Verification

    Sodium heparin (MW 15kDa); Sodium heparinate (MW 15kDa)

    		 Thrombin Factor Xa Autophagy Cardiovascular Disease
    Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa. Heparin sodium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa .
    Heparin sodium salt (MW 15kDa)
  • HY-P1536
    Thrombin Receptor Activator for Peptide 5 (TRAP-5)

    		Protease Activated Receptor (PAR) Cardiovascular Disease
    Thrombin Receptor Activator for Peptide 5 (TRAP-5) is also called Coagulation Factor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), used in the research of coronary heart disease (CHD).
    Thrombin Receptor Activator for Peptide 5 (TRAP-5)
  • HY-137431
    Asundexian
    1 Publications Verification

    BAY-2433334

    		 Factor Xa Cardiovascular Disease
    Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC50 of 1 nM .
    Asundexian
  • HY-113958R
    Difethialone (Standard)

    		TrxR Others
    Difethialone (Standard) is the analytical standard of Difethialone. This product is intended for research and analytical applications. Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
    Difethialone (Standard)
  • HY-116282D
    Dextran sulfate sodium salt (MW 450000-550000)

    DSS (MW 450000-550000); DXS (MW 450000-550000)

    		 HIV Apoptosis Others
    Dextran sulfate sodium salt (MW 450000-550000) is a polymer of anhydroglucose with a molecular weight range of 450000-550000. Dextran sulfate sodium salt (MW 450000-550000) can effectively enrich precipitated cells and can be used to isolate neutrophils from human and rat blood. Dextran sulfate sodium salt (average MW 500000) can effectively enhance the conversion activity of coagulation factor XIIa (FXIIa) to induce hepatocyte growth factor (HGF) and increase the specific activity of FXIIa.
    Dextran sulfate sodium salt (MW 450000-550000)
  • HY-P2751
    Elastase, Human leukocytes

    		Others Others
    Elastase, Human leukocytes is a serine protease present in the nitrogen-loving granules of neutrophils. Elastase, Human leukocytes potential substrates include almost all components of the extracellular matrix, as well as a variety of proteins such as coagulation factors, complement, immunoglobulins and cytokines. It has a strong proteolytic function and participates in the pathogenesis of inflammatory tissue damage .
    Elastase, Human leukocytes
  • HY-129056
    Melagatran

    		Thrombin Cardiovascular Disease
    Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia . Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion .
    Melagatran
  • HY-10264
    Edoxaban
    5+ Cited Publications

    DU-176

    		 Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .
    Edoxaban
  • HY-10264B
    Edoxaban tosylate monohydrate
    5+ Cited Publications

    DU-176b monohydrate

    		 Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .
    Edoxaban tosylate monohydrate
  • HY-10264A
    Edoxaban tosylate
    5+ Cited Publications

    DU-176b

    		 Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research .
    Edoxaban tosylate
  • HY-10264C
    Edoxaban hydrochloride

    DU-176 hydrochloride

    		 Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research .
    Edoxaban hydrochloride
  • HY-145405
    C12-200
    5+ Cited Publications

    		 Liposome Others
    C12-200 is a type of ionizable cationic lipid and helper lipid commonly used for mRNA delivery. In the hemophilia B mouse model, mRNA encoding human erythropoietin (EPO) and coagulation factor IX (FIX) can be successfully delivered and expressed using C12-200. C12-200 is utilized in research related to hemophilia B .
    C12-200
  • HY-162646
    FXIIa-IN-5

    		Thrombin Cardiovascular Disease
    FXIIa-IN-5 (Compound 4J) is an orally active, selective inhibitor for factor XIIa (FXIIa), with IC50 of 21 nM. FXIIa-IN-5 inhibits the intrinsic coagulation pathways, and exhibits anti-inflammatory and antithrombotic activity in Carrageenan (HY-125474)-induced mice thrombosis models. FXIIa-IN-5 exhibits moderate pharmacokinetic characteristics and slightly toxicity (at 100 mg/kg) .
    FXIIa-IN-5
  • HY-10264R
    Edoxaban (Standard)

    		Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (Standard) is the analytical standard of Edoxaban. This product is intended for research and analytical applications. Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .
    Edoxaban (Standard)
  • HY-125856
    Milvexian
    1 Publications Verification

    BMS-986177; JNJ-70033093

    		 Factor Xa Cardiovascular Disease
    Milvexian is an orally bioavailable, small-molecule, reversible, direct antagonists of factor Xia, with the Ki of 0.11, 0.38, 0.64, 490, 350 nM for human, rabbit, dog, rat, mouse, respectively. Milvexian shows anti-thrombosis activity in vitro and in vivo, and can be used for thrombus study .
    Milvexian
  • HY-125856A
    Milvexian TFA

    BMS-986177 TFA; JNJ-70033093 TFA

    		 Factor Xa Cardiovascular Disease
    Milvexian TFA (BMS-986177 TFA) is a factor XIa inhibitor with biological activity to prevent venous thromboembolism. Milvexian TFA was effective in reducing the occurrence of venous thromboembolism in patients undergoing knee replacement surgery. Milvexian TFA has good selectivity and shows significant inhibitory effects on plasma kallikrein and trypsin. Milvexian TFA has a bioavailability of 32%, which means it has a high absorption rate in the body. Milvexian TFA showed a relatively low risk of bleeding in clinical trials .
    Milvexian TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: